GUGGENHIME ANDREW 4

What Happened
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte (PCVX), reported transactions on 2026-06-18. He exercised options to acquire 10,000 shares at $5.35 per share (cost $53,500) and sold 10,000 shares in the open market at $53.00 per share for gross proceeds of $530,000. The filing also shows a 10,000-share derivative conversion/disposition reported at $0. The sale was executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-06-18.
• Exercises: 10,000 shares exercised at $5.35 (total $53,500). Option reported as fully vested and exercisable (F3).
• Sale: 10,000 shares sold at $53.00 (gross proceeds $530,000); sale effected under a Rule 10b5-1 plan adopted March 4, 2026 (F1).
• Derivative line: 10,000-share exercise/conversion reported at $0 (recorded as a derivative disposition).
• Ownership after transaction: not specified in the provided data. Note some shares are held by ALG 2025 GRAT HOLDINGS LLC, owned by a grantor retained annuity trust for which Guggenhime is annuitant/trustee (F2).
• Filing timeliness: report period and filing date are the same (2026-06-18); no late-file indication provided.

Context
This shows an "exercise-and-sell" sequence: options were exercised and at least some of the resulting shares were sold the same day, a routine pattern for option holders to cover exercise costs or diversify. The 10b5-1 note means the sale was pre-arranged under a trading plan, which can help avoid questions about trading on material nonpublic information. The $0 derivative line likely reflects the internal conversion/settlement mechanics of the option/derivative and does not indicate additional cash payment.